High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines
1996

MDM2 Levels and p53 in Mesothelioma

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): S Ungar, A Van de Meeren, L Tammilehto, K Linnainmaa, K Mattson, B I Gerwin

Primary Institution: National Cancer Institute

Hypothesis

High levels of MDM2 might alter p53 and retinoblastoma tumour-suppressor function in mesothelioma.

Conclusion

High levels of MDM2 are not responsible for inactivating the functions of wild-type p53 or the retinoblastoma gene product during the pathogenesis of malignant mesothelioma.

Supporting Evidence

  • Previous studies indicated that alterations in the p53 gene are common in various cancers.
  • MDM2 was shown to bind to p53 and interfere with its function.
  • None of the mesothelioma cell lines showed amplification of the mdm2 gene.
  • Five out of six mesothelioma lines showed significant induction of p21WAF1 and p53 after radiation exposure.

Takeaway

This study looked at cancer cells to see if a protein called MDM2 affects another protein called p53, which helps control cell growth. They found that MDM2 doesn't actually stop p53 from working in these cancer cells.

Methodology

The study involved testing 18 mesothelioma cell lines for MDM2 gene amplification and protein expression, comparing them with normal human mesothelial cells.

Limitations

The study only examined a limited number of mesothelioma cell lines and did not explore other potential factors affecting p53 and Rb pathways.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication